Ulinastatin, also known as urinary trypsin inhibitor, is a kind of
glycoprotein from human body, which is involved in the regulation of
inflammatory response in blood. It is a kind of innate immune-related substance,
which can inhibit the excessive activation of white blood cells, protect
vascular endothelium and basement membrane, and inhibit the increase of vascular
permeability. It is clinically used as a therapeutic drug for acute
The total content of ulinastatin in the blood is very rich, which mainly exists in the former body form. The inactive precursor has a high molecular weight and weak affinity with proteolytic enzymes. It is not easy to be filtered out into the urine by the kidney, which is the way for the body to store ulinastatin. Free ulinastatin has inhibitory activity on proteolytic enzymes released in various inflammatory reactions, accounting for 2% ~ 10% of the total content.
Ulinastatin was made for clinical use in Japan in 1986 and in our country in 1999. In clinical practice, a new application field has been developed. The initial anti-pancreatitis, anti-shock and defensive surgical stimulation have been developed into a widely used drug in the field of acute and critical diseases, specializing in anti-inflammatory and viscera protection.
Ulinastatin is different from the therapeutic drugs that antagonizes one or several cytokines, and does not bring side effects such as immune suppression, stress ulcer bleeding and osteoporosis like glucocorticoids. As an in vivo anti-inflammatory complementary therapy drug, the severity of the disease is positively correlated with the dose to be supplemented. SIRS are regulated by a complex signal network, and single drugs antagonizing a certain cytokine are ineffective. Clinical practice has shown that ulinastatin supplementation with SIRS in vitro successfully blocks and interferes the development of SIRS by inhibiting the inflammatory reactivation-related hydrolases and the over-activation of inflammatory cells!
At present, ulinastatin is widely used in the treatment of SAP, CARDIopulmonary resuscitation, severe multiple injuries, compound injuries, burns, sepsis and shock.